

## **Asia-Pacific Pemphigus Vulgaris Market**

Market Report | 2025-06-01 | 350 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### **Report description:**

The Asia-pacific pemphigus vulgaris market is expected to reach USD 140.96 million by 2032 from USD 67.44 million in 2024, growing at a CAGR of 9.8% in the forecast period of 2025 to 2032.

Market Segmentation:

Asia-Pacific Pemphigus Vulgaris Market Segmentation, By Diagnosis and Treatment (Diagnosis and Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy), Countries (China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, New Zealand, Taiwan, Hong Kong, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2032

Overview of Asia-Pacific Pemphigus Vulgaris Market Dynamics:

Driver

- Emerging treatment options for pemphigus vulgaris

Restraint

- Stringent regulatory guidelines for pemphigus vulgaris drug approval

Opportunity

- Increasing demand for personalized medicine□□

Market Players:

The key market players operating in the Asia-pacific pemphigus vulgaris market are listed below:

- Merck & Co., Inc. (U.S.)
- Sanofi (France)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- AstraZeneca (U.K.)
- GRIFOLS SA (Spain)
- Zydus Group (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- GSK plc. (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- Celltrion (South Korea)
- Lilly (U.S.)
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Fresenius Kabi AG (Germany)
- Rakshit Drugs Private Limited (India)
- Amgen Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- CSL (Australia)
- Baxter (U.S.)
- Accord Healthcare (U.K.)
- DAEWOONG PHARMACEUTICAL CO., LTD. (South Korea)
- SUNPHARMA.NS (India)
- Cipla Health Ltd (India)

## Table of Contents:

### TABLE OF CONTENTS

1	INTRODUCTION	21
1.1	OBJECTIVES OF THE STUDY	21
1.2	MARKET DEFINITION	21
1.3	OVERVIEW	21
1.4	LIMITATIONS	22
1.5	MARKETS COVERED	23
2	MARKET SEGMENTATION	26
2.1	MARKETS COVERED	26
2.2	GEOGRAPHICAL SCOPE	27
2.3	YEARS CONSIDERED FOR THE STUDY	28
2.4	CURRENCY AND PRICING	28
2.5	DBMR TRIPOD DATA VALIDATION MODEL	29
2.6	MULTIVARIATE MODELLING	32
2.7	PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	33
2.8	DBMR MARKET POSITION GRID	35
2.9	MARKET END USER COVERAGE GRID	36
2.10	VENDOR SHARE ANALYSIS	37
2.11	SECONDARY SOURCES	38
2.12	ASSUMPTIONS	39
3	EXECUTIVE SUMMARY	40
4	PREMIUM INSIGHTS	45
4.1	PESTAL ANALYSIS	46

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.2	PORTERS FIVE FORCES ANALYSIS	47
4.3	PATENT ANALYSIS	48
4.3.1	PATIENT FLOW DIAGRAM	49
4.3.2	KEY PRICING STRATEGIES	50
4.3.3	FUTURE THERAPIES	50
4.3.4	KEY PATIENT ENROLLMENT STRATEGIES	51
4.4	ASIA-PACIFIC CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET	53
4.5	SUPPLY CHAIN ECOSYSTEM	59
4.6	HEALTHCARE TARIFFS & IMPACT ON THE MARKET: ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET	61
4.7	EPIDEMIOLOGY: ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET	64
4.7.1	INCIDENCE BY GENDER	64
4.7.2	TREATMENT RATE	64
4.7.3	MORTALITY RATE	64
4.7.4	PATIENT TREATMENT SUCCESS RATES	65
5	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: REGULATIONS	66
6	MARKET OVERVIEW	72
6.1	DRIVERS	74
6.1.1	EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS	74
6.1.2	RISING PREVALENCE OF AUTOIMMUNE DISORDERS	75
6.1.3	GROWING AWARENESS OF PEMPHIGUS VULGARIS	76
6.1.4	GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS	77
6.2	RESTRAINTS	78
6.2.1	STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL	78
6.2.2	HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES	79
6.3	OPPORTUNITIES	80
6.3.1	INCREASING DEMAND FOR PERSONALIZED MEDICINE	80
6.3.2	INCREASING HEALTHCARE FACILITIES	81
6.3.3	RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT	82
6.4	CHALLENGES	83
6.4.1	RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS	83
6.4.2	LACK OF REIMBURSEMENT AND COVERAGE POLICIES	84
7	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT	85
7.1	OVERVIEW	86
7.2	TREATMENT	89
7.3	DIAGNOSIS	91
8	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE	92
8.1	OVERVIEW	93
8.2	ADULTS	96
8.3	GERIATRIC	96
8.4	PEDIATRIC	97
9	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER	98
9.1	OVERVIEW	99
9.2	HOSPITALS	102
9.3	SPECIALTY CLINICS	102
9.4	RESEARCH INSTITUTES	103
9.5	OTHERS	103
10	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL	104

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1	OVERVIEW	105
10.2	HOSPITALS PHARMACY	108
10.3	RETAIL PHARMACY	108
10.4	ONLINE PHARMACY	109
11	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY REGION	110
11.1	ASIA-PACIFIC	112
11.1.1	CHINA	116
11.1.2	INDIA	119
11.1.3	SOUTH KOREA	122
11.1.4	MALAYSIA	125
11.1.5	JAPAN	128
11.1.6	AUSTRALIA	131
11.1.7	SINGAPORE	134
11.1.8	THAILAND	137
11.1.9	INDONESIA	140
11.1.10	NEW ZEALAND	143
11.1.11	TAIWAN	146
11.1.12	PHILIPPINES	149
11.1.13	HONG KONG	152
11.1.14	REST OF ASIA-PACIFIC	155
12	ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE	156
12.1	COMPANY SHARE ANALYSIS: ASIA-PACIFIC	
13	SWOT ANALYSIS	157
14	COMPANY PROFILE	158
14.1	MERCK AND CO. INC.	158
14.1.1	COMPANY SNAPSHOT	158
14.1.2	REVENUE ANALYSIS	158
14.1.3	COMPANY SHARE ANALYSIS	159
14.1.4	PRODUCT PORTFOLIO	159
14.1.5	RECENT DEVELOPMENTS	160
14.2	SANOFI	161
14.2.1	COMPANY SNAPSHOT	161
14.2.2	REVENUE ANALYSIS	161
14.2.3	COMPANY SHARE ANALYSIS	162
14.2.4	PRODUCT PORTFOLIO	162
14.2.5	RECENT DEVELOPMENT	163
14.3	REGENERON PHARMACEUTICALS INC.	164
14.3.1	COMPANY SNAPSHOT	164
14.3.2	REVENUE ANALYSIS	164
14.3.3	COMPANY SHARE ANALYSIS	165
14.3.4	PRODUCT PORTFOLIO	165
14.3.5	RECENT DEVELOPMENTS	166
14.4	JOHNSON & JOHNSON SERVICES, INC.	167
14.4.1	COMPANY SNAPSHOT	167
14.4.2	REVENUE ANALYSIS	167
14.4.3	COMPANY SHARE ANALYSIS	168
14.4.4	PRODUCT PORTFOLIO	168

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.4.5	RECENT DEVELOPMENT	169
14.5	ASTRAZENECA	170
14.5.1	COMPANY SNAPSHOT	170
14.5.2	REVENUE ANALYSIS	170
14.5.3	COMPANY SHARE ANALYSIS	171
14.5.4	PRODUCT PORTFOLIO	171
14.5.5	RECENT DEVELOPMENT	172
14.6	ABBVIE INC.	173
14.6.1	COMPANY SNAPSHOT	173
14.6.2	REVENUE ANALYSIS	173
14.6.3	PRODUCT PORTFOLIO	174
14.6.4	RECENT DEVELOPMENT	175
14.7	ACCORD HEALTHCARE	177
14.7.1	COMPANY SNAPSHOT	177
14.7.2	PRODUCT PORTFOLIO	177
14.7.3	RECENT DEVELOPMENT	177
14.8	AMGEN INC.	178
14.8.1	COMPANY SNAPSHOT	178
14.8.2	REVENUE ANALYSIS	178
14.8.3	PRODUCT PORTFOLIO	179
14.8.4	RECENT DEVELOPMENT	180
14.9	ARTIVA BIOTHERAPEUTICS, INC.	181
14.9.1	COMPANY SNAPSHOT	181
14.9.2	REVENUE ANALYSIS	181
14.9.3	PRODUCT PIPELINE PORTFOLIO	182
14.9.4	RECENT DEVELOPMENT	182
14.10	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	183
14.10.1	COMPANY SNAPSHOT	183
14.10.2	PRODUCT PORTFOLIO	183
14.10.3	RECENT DEVELOPMENT	183
14.11	BAXTER	184
14.11.1	COMPANY SNAPSHOT	184
14.11.2	REVENUE ANALYSIS	184
14.11.3	PRODUCT PORTFOLIO	185
14.11.4	RECENT DEVELOPMENT	185
14.12	BIOXPRESS THERAPEUTICS SA	186
14.12.1	COMPANY SNAPSHOT	186
14.12.2	PRODUCT PORTFOLIO	186
14.12.3	RECENT DEVELOPMENT	186
14.13	CABALETTA BIO INC.	187
14.13.1	COMPANY SNAPSHOT	187
14.13.2	REVENUE ANALYSIS	187
14.13.3	PRODUCT PORTFOLIO	187
14.13.4	RECENT DEVELOPMENT	188
14.14	CIPLA HEALTH LTD	189
14.14.1	COMPANY SNAPSHOT	189
14.14.2	PRODUCT PORTFOLIO	189

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.14.3 RECENT DEVELOPMENTS 189  
14.15 CELLTRION 190  
14.15.1 COMPANY SNAPSHOT 190  
14.15.2 REVENUE ANALYSIS 190  
14.15.3 PRODUCT PORTFOLIO 191  
14.15.4 RECENT DEVELOPMENTS 192  
14.16 CSL 193  
14.16.1 COMPANY SNAPSHOT 193  
14.16.2 REVENUE ANALYSIS 193  
14.16.3 PRODUCT PORTFOLIO 194  
14.16.4 RECENT DEVELOPMENT 194  
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD. 195  
14.17.1 COMPANY SNAPSHOT 195  
14.17.2 REVENUE ANALYSIS 195  
14.17.3 PRODUCT PORTFOLIO 196  
14.17.4 RECENT DEVELOPMENT 196  
14.18 F. HOFFMANN- LA ROCHE LTD. 197  
14.18.1 COMPANY SNAPSHOT 197  
14.18.2 REVENUE ANALYSIS 197  
14.18.3 PRODUCT PORTFOLIO 198  
14.18.4 RECENT DEVELOPMENT/NEWS 198  
14.19 FRESENIUS KABI AG 200  
14.19.1 COMPANY SNAPSHOT 200  
14.19.2 REVENUE ANALYSIS 200  
14.19.3 PRODUCT PORTFOLIO 201  
14.19.4 RECENT DEVELOPMENT 201  
14.20 GSK PLC 203  
14.20.1 COMPANY SNAPSHOT 203  
14.20.2 REVENUE ANALYSIS 203  
14.20.3 PRODUCT PORTFOLIO 204  
14.20.4 RECENT DEVELOPMENT 204  
14.21 GRIFOLS, S.A. 206  
14.21.1 COMPANY SNAPSHOT 206  
14.21.2 REVENUE ANALYSIS 206  
14.21.3 PRODUCT PORTFOLIO 207  
14.21.4 RECENT DEVELOPMENT 207  
14.22 INCYTE 208  
14.22.1 COMPANY SNAPSHOT 208  
14.22.2 REVENUE ANALYSIS 208  
14.22.3 PRODUCT PORTFOLIO 209  
14.22.4 RECENT DEVELOPMENT 209  
14.23 NOVARTIS AG 210  
14.23.1 COMPANY SNAPSHOT 210  
14.23.2 REVENUE ANALYSIS 210  
14.23.3 PRODUCT PORTFOLIO 211  
14.23.4 RECENT DEVELOPMENT 211  
14.24 LILLY 212

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.24.1 COMPANY SNAPSHOT 212  
14.24.2 REVENUE ANALYSIS 212  
14.24.3 PRODUCT PORTFOLIO 213  
14.24.4 RECENT DEVELOPMENT 213  
14.25 OCTAPHARMA AG 214  
14.25.1 COMPANY SNAPSHOT 214  
14.25.2 REVENUE ANALYSIS 214  
14.25.3 PRODUCT PORTFOLIO 215  
14.25.4 RECENT DEVELOPMENT/NEWS 215  
14.26 PFIZER INC. 216  
14.26.1 COMPANY SNAPSHOT 216  
14.26.2 REVENUE ANALYSIS 216  
14.26.3 PRODUCT PORTFOLIO 217  
14.26.4 RECENT DEVELOPMENT 217  
14.27 RAKSHIT DRUGS PVT. LTD 218  
14.27.1 COMPANY SNAPSHOT 218  
14.27.2 PRODUCT PORTFOLIO 218  
14.27.3 RECENT DEVELOPMENT 219  
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD. 220  
14.28.1 COMPANY SNAPSHOT 220  
14.28.2 REVENUE ANALYSIS 220  
14.28.3 PRODUCT PORTFOLIO 221  
14.28.4 RECENT DEVELOPMENT 221  
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD 222  
14.29.1 COMPANY SNAPSHOT 222  
14.29.2 REVENUE ANALYSIS 222  
14.29.3 PRODUCT PORTFOLIO 223  
14.29.4 RECENT DEVELOPMENT 223  
14.30 ZYDUS GROUP 225  
14.30.1 COMPANY SNAPSHOT 225  
14.30.2 REVENUE ANALYSIS 225  
14.30.3 PRODUCT PORTFOLIO 226  
14.30.4 RECENT DEVELOPMENT 227  
15 QUESTIONNAIRE 228  
16 RELATED REPORTS 231  
?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Asia-Pacific Pemphigus Vulgaris Market**

Market Report | 2025-06-01 | 350 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com